GoodRx Receives Overweight Rating and Higher Price Target from Wells Fargo Analysts
Monday, 25 March 2024, 20:24
Reasons Behind GoodRx's Surge Today
The prescription-drug upstart, GoodRx (NASDAQ: GDRX), experienced a 7.5% rally after receiving an upgrade from analysts at Wells Fargo.
Upgrade Details
- Wells Fargo raised the rating from 'equal weight' to 'overweight.'
- The price target was increased from $7.50 to $10.
Positive Outlook: Analysts expect GoodRx to outperform its peers and close the valuation gap, setting up for significant growth in the upcoming months.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.